MetaStat Discussed in Medscape and Other News Outlets

Interviews Spotlight Importance of Company’s Diagnostic Tests for Predicting Metastasis in Patients with Breast Cancer

MetaStat, Inc. (OTCQB: MTST), a molecular diagnostic company focused on developing and commercializing epigenetic-based diagnostic tests for early and reliable prediction of systemic metastasis, was featured in Medscape.com, WNYM-AM, WHCR-FM and the Boston Business Journal.

On March 19, CEO Oscar L. Bronsther, M.D. was quoted in a Medscape.com article titled “Breast Biopsy Uncertainties for DCIS and Atypia.” Dr. Bronsther spoke on the significance of a new JAMA study finding disagreement among pathologists when diagnosing ductal carcinoma in situ or atypia on the basis of breast biopsies. Dr. Bronsther said, “Overall, the disparity is unsettling. It may result in either the overtreatment or undertreatment of women with newly diagnosed (and potentially inappropriately diagnosed) breast lesions. Although the pathologists have substantial experience analyzing biopsy results, there is still a measure of subjective judgment involved. It is important to understand that the morphological criteria and definition of cancer have not changed for decades. It is inevitable that in the absence of more detailed analysis, opinions among the two groups regarding specific slides will vary.”

To read the Medscape article in its entirety, please visit the following link: http://www.medscape.com/viewarticle/841745#vp_1 A one-time registration is needed, which is free of charge.

On March 29, WNYM-AM, a New York City radio station, aired an interview with Dr. Bronsther on “World Health News with Dr. Samadi,” during which Dr. Bronsther outlined the need for better diagnostic tests for women with breast cancer and the specific advantages of the Company’s MetaSite Breast™ and MenaCalc™ assays.

To listen to the WNYM interview in its entirety, please visit the following link: https://soundcloud.com/world-health-news/dr-samadi-talks-with-dr-oscar

To view a video of the WNYM interview, please visit the following link: https://www.youtube.com/watch?v=IZQkb-dDn6o

On March 25 and 29, WHCR-FM, a community radio station owned and operated by The City College of New York, aired an interview with Dr. Bronsther on its program “Your Family’s Health,” during which he once again discussed the need for better diagnostic tests and the Company’s assays.

On February 6 and February 20, the Boston Business Journal published articles featuring MetaStat. The February 6 article, “MetaStat aims at ‘next level in cancer diagnostics’ with new partnership,” spotlights the Company’s agreement with Kaiser Foundation Hospitals to get de-identified tissue samples, clinical data and medical histories for up to 500 patients to test the Company's diagnostic assays. In the February 20 article, “Signs of Health in the Diagnostics Industry,” Dr. Bronsther is quoted on the field of oncology diagnostics, saying, “That’s where all the money is at now. It’s probably the most financially and clinically interesting [among fields likely to attract investors].”

To read the February 6 Boston Business Journal article in its entirety, please visit: http://www.bizjournals.com/boston/blog/bioflash/2015/02/metastat-aims-at-next-level-in-cancer-diagnostics.html

To read the February 20 Boston Business Journal article in its entirety, please visit: http://www.bizjournals.com/boston/print-edition/2015/02/20/signs-of-health-in-the-diagnostics-industry.html?page=all

The articles and interviews at the links above are provided for informational purposes only. MetaStat, Inc. is not responsible for the content of the linked articles and interviews.

About MetaStat, Inc.

MetaStat, Inc. (MTST) is a molecular diagnostic company that develops and commercializes diagnostic tests for early and reliable prediction of systemic metastasis, the process by which cancer spreads from a primary tumor through the bloodstream to other areas of the body. MetaStat is focused on breast, prostate, lung and colorectal cancers, where systemic metastasis is responsible for approximately 90% of all deaths. The company’s function-based diagnostic platform technology is based on the identification and understanding of the pivotal role of the mena protein and its isoforms, a common pathway for the development of systemic metastatic disease in all epithelial-based solid tumors. Both the MetaSite Breast™ and MenaCalc™ assays are designed to accurately stratify patients based on their individual risk of metastasis and to provide physicians with clinically actionable information to better "customize" cancer treatment. MetaStat’s testing platform improves treatment planning decisions by positively identifying patients with a high-risk of metastasis who need aggressive therapy and by sparing patients with a low-risk of metastasis from the harmful side effects and expense of chemotherapy. The company is based in Boston.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including those set forth in the company's Form 10-K filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the company undertakes no obligation to update such statements.

Media:Dian Griesel Int’l. for MetaStatSusan Forman, 212-825-3210sforman@dgicomm.comorInvestors:MetaStat, Inc.Douglas Hamilton, (917) 597-4164Dhamilton@metastat.com

MetaStat (CE) (USOTC:MTST)
過去株価チャート
から 1 2025 まで 2 2025